ARCHIVES

Stone(y) Silence Didn’t Save His Job; Niamd’s Rall Rumored as Top Choice As New NIH Director

This article is from The Cancer Letter archive.

Vol. 01 No. 46 | December 20, 1974

Download PDF Visit The Full Archive

Related Articles

FDA Advisors Uphold Broad Mandate To Limit Use Of ESA Products In Cancer Indications.

May 11, 2007

Max Wicha Describes Michigan’s Restructuring Planning For Growth

May 7, 1999

NCI-Approved Clinical Trials

November 24, 2006

Canadian Products Anticancer Drugs In Plant Culture

April 22, 1983

Device Shortens Time To Make T Cells For Immunotherapy

March 27, 2009

GA101 Associated with Better PFS In Phase III Trial Versus Rituximab in CLL

July 26, 2013